Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Rapid Reviews in Oncology: Breast Cancer Highlights

Release Date: June 17, 2009| Expiration Date: June 17, 2010
2 AMA PRA Category 1 Credit(s)™| Jun 4, 2009, Multiple Locations Nationwide

Lecture Overview

This on-demand Webcast is from the Rapid Reviews in Oncology: Breast Cancer Highlights program held on June 4, 2009.

The Rapid Reviews in Oncology: Breast Cancer Highlights program will cover new data on breast cancer diagnosis and treatment from recent international meetings. This program is designed to answer key questions on potentially practice-changing developments in the field of breast oncology and to provide a framework for integrating these developments into daily practice. Topics will include locoregional therapy, risk assessment and prognostic/predictive factors. In addition, the latest advances in chemotherapy, hormonal therapy, targeted therapy, novel agents, and combination regimens being evaluated in patients with early-stage and advanced breast cancer will also be discussed. Presentations of key data will be followed by an interactive session where participants will have the opportunity to ask questions of experts in the field of breast cancer.

This educational activity is designed to be of high clinical utility to medical oncologists, surgical oncologists, and radiation oncologists with an interest in the treatment of breast cancer. Physicians’ assistants, research nurses, and fellows with an interest in the treatment of patients with breast cancer are also invited to participate.

Upon completion of this educational activity, you should be able to:

  • Evaluate genomic and proteomic tools for the assessment of recurrence risk, prediction of benefit from chemotherapy, and individualization of therapeutic decision making
  • Debate adjuvant endocrine options, including timing and sequencing of aromatase inhibitors in adjuvant regimens and the integration of bone-targeted agents for postmenopausal patients
  • Assess data, including patient selection and alternative dosing schedules, from clinical trials investigating adjuvant chemotherapy regimens
  • Discuss the biologic rationale for HER2-targeted therapies as well as recent results with novel HER2-directed agents in early-stage and advanced/metastatic breast cancer
  • Individualize the management of patients with chemotherapy-naïve and chemotherapy-refractory advanced breast cancer, including the incorporation of novel cytotoxic and biologic agents
  • Review novel classes of targeted biologic agents and cytotoxic therapies currently under investigation for the treatment of metastatic breast cancer
  • Describe currently available and investigational agents for improving bone health in patients undergoing endocrine treatment for breast cancer
  • Guide patients to promising clinical trials

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. View the Flash video presentations and slides.
  4. Complete the Posttest
  5. Answer the evaluation questions
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

Complete the test(s) and evaluation by June 17, 2010 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from the Rapid Reviews in Oncology: Breast Cancer Highlights program have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Adam Brufsky, MD, PhD
Paid Consultant – Novartis Pharmaceuticals Corporation
Speaker’s Bureau – Novartis Pharmaceuticals Corporation

William J. Gradishar, MD, FACP
Paid Consultant – Abraxis Bioscience, LLC; AstraZeneca; Novartis Pharmaceuticals Corporation; Pfizer Inc.

Eleftherios Mamounas, MD, MPH, FACS
Paid Consultant – Agendia; Genentech, Inc.; Genomic Health, Inc.; GlaxoSmithKline; Pfizer, Inc.; sanofi-aventis U.S.
Speaker’s Bureau – Genentech, Inc.; Genomic Health, Inc.; sanofi-aventis U.S.

Joyce O’Shaughnessy, MD
Paid Consultant – Amgen; Bristol-Myers Squibb Company; Genentech, Inc.; Novartis Pharmaceuticals Corporation
Speaker’s Bureau – Abraxis Bioscience, LLC; AstraZeneca; Bristol-Myers Squibb Company; Eli Lilly and Company; sanofi-aventis U.S.

PER Editorial Staff
No relevant relationships to disclose

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physician’s Desk Reference.

Commercial Support

Educational grants for this activity were provided by Abraxis BioScience, Genentech BioOncology, Bristol-Myers Squibb, and Novartis Oncology

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Additional software requirements include:

Macintosh Users
Compatible Web browsers include:

Additional software requirements include:

Disclaimer

The views and opinions expressed in this learning activity are those of the presenters and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the presenters and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2009 by Physicians’ Education Resource.

All correspondence should be directed to:
Editor, Rapid Reviews in Oncology: Breast Cancer Highlights
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

Educational Grants

An educational grant for this activity was provided by:


  1. Genentech BioOncology
  2. Novartis Oncology
  3. Bristol-Myers Squibb
  4. Abraxis BioScience, Inc.